Berkeley CA, US, 22 Mar 2010 16:15 CET
Expansion of business development activities to add value to existing client relationships and meet growing demand for the company’s brand of implantable polyurethanes.
DSM Biomedical, a global leader in biomedical materials science, today announced the expansion of its resources and operations in the United States (U.S.) and Europe to support the growing demand for the company’s portfolio of innovative polyurethanes for chronically implanted medical devices in the regions.
Earlier this year, DSM Biomedical expanded the role of two of its Business Development Managers, one in the U.S. and one in Europe, and an Application Development Manager, based in Europe, to enhance the company’s client relationships in the U.S. and Europe and offer an improved level of on-the-ground technical assistance for customers. In their newly expanded positions, all three experts will be responsible for key business development activities, representing the broader portfolio of DSM Biomedical, including managing customer relationships and providing technical assistance in the European and U.S. markets.
“Medical device manufacturers are fast recognizing a growing need for high performance, cost effective, and easy to implant devices produced from proven materials that have the potential to improve patient outcomes,” said Bob Ward, President and CEO, DSM PTG, part of DSM Biomedical. “With the company’s 20 years of experience developing innovative solutions for the medical device market as well as our recent investment in business and application development, we hope to not only offer a broader portfolio of solutions but also enable a faster material selection and design process based on proven materials, and ultimately device approvals for our clients and patients”.
DSM Biomedical has demonstrated a successful track record of working with medical device manufacturers to develop solutions for the pharmaceutical, life sciences and medical device industries, including introducing new products that employ its implantable polymers. The company recently launched the next generation of its polymers Bionate® II PCU as well as an alternative coating technology VitroStealth™, both offering additional improved benefits to its customers. Numerous medical devices and technologies benefit from DSM Biomedical’s platform of technologies including it’s innovation in polymers for pacemakers, neurostimulation devices, prosthetic disks and spinal stabilization devices, artificial hearts, catheters, and glucose sensors, among others.
DSM Biomedical’s business expansion comes on the heels of the company’s recent announcement that it signed nine new license agreements in 2009 for its well known Bionate, BioSpan®, CarboSil®, Elasthane™ and PurSil® brands of biomedical polymers, and formed eight new development partnerships with medical device companies in the last year alone. These contracts underline an upward trend among medical device developers in enrolling material specialists to develop and license new polymer technologies essential to increasing the value, performance, and quality of their products.
Providing customers with proprietary materials-based solutions to create innovative solutions for the market’s most critical medical needs, the company’s scientists work with both start-ups and large medical device manufacturers in the U.S. and Europe in fields including cardiovascular, orthopedic, ophthalmic, wound care and disease prevention and treatment. DSM Biomedical has a long history of supporting customers throughout the various phases of development, prototyping, manufacturing and processing of product commercialization. Additionally, the company’s quality system is certified to the ISO 9001:2000 and ISO 13845:2003 standards, ensuring its partners expertise in quality and regulatory compliance.